BioSpace1d
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Pharm Exec2d
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...
PMLiVE1d
Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...
FiercePharma3d
Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Hosted on MSN1d
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Pharmabiz1d
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...
Nasdaq3d
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease ...
Taiwan News3d
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries ; Evrysdi tablet can be stored at room temperature and offers the same demon ...
Yahoo Finance3d
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Basel, 12 February 2025 - Roche (SIX: RO, ROG ... tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA.
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...